UNSPSC 51372009: Hydromorphinol

This classification denotes an opioid receptor agonist with the molecular formula C17H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1O00P9X5C1, chemically known as morphinan-3,6,14-triol, 4,5-epoxy-17-methyl-, (5.alpha.,6.beta.)- but generally known as hydromorphinol, which bears US NIH Compound Identifier 627484. European Medicines Agency schedules Hydromorphinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08069MIG. The term HYDROMORPHINOL is an International Non-Proprietary Name.

UNSPSC 51372009 Hydromorphinol is a Commodity code that appears to capture pharmaceutical products, though recent state and local solicitations under this code show limited direct activity specific to the nominal product. The recent opportunities posted instead reflect broader pharmaceutical procurement across naloxone (an opioid antagonist), generic multi-source pharmaceuticals, and over-the-counter products. State and local issuers purchasing under related pharmaceutical codes include county health departments (Seminole County, Florida) and state HHS agencies and cooperative purchasing entities (Texas Health and Human Services Commission, Minnesota Multistate Cooperative Purchasing Alliance). Work solicited ranges from emergency-response medications like naloxone through community health distribution to large-scale generic pharmaceutical contracting with authorized wholesalers and direct-to-manufacturer prescription programs. Purchasing entities require compliance with DEA regulations, Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), and federal procurement standards including E-Verify, insurance coverage, and drug-free workplace certification.

Recent activity spans Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and quarterly deliveries to Sanford, Florida. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal deadline and an effective date of July 1, 2026; this RFP applies to participating state and local facilities across multiple states including Oregon. Vendors must supply through three authorized wholesalers and comply with NDC coding, cGMP certification, and DSCSA requirements, with evaluation weighted heavily toward price competitiveness (75 percent).